Inhaled antibiotics for the treatment of chronic bronchopulmonaryPseudomonas aeruginosainfection in cystic fibrosis: systematic review of randomised controlled trials

Regulatory Aspects of Phase 3 Endpoints for New Inhaled Antibiotics for Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections

(2012) Alan Bruce Montgomery et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

WS5.5 A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection

(2012) M. Goldman et al.   Journal of Cystic Fibrosis

WS5.6 A challenging double-blind, placebo-controlled study of tobramycin inhalation powder in cystic fibrosis: results of the EDIT trial

(2012) I. Galeva et al.   Journal of Cystic Fibrosis

67 Trends in health-related quality of life (HRQoL) in cystic fibrosis with tobramycin inhalation powder: the EDIT trial

(2012) A.L. Quittner et al.   Journal of Cystic Fibrosis

Treatment of lung infection in patients with cystic fibrosis: Current and future strategies

(2012) Gerd Döring et al.   Journal of Cystic Fibrosis

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

(2012) Baroukh M. Assael et al.   Journal of Cystic Fibrosis

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

(2012) Antje Schuster et al.   THORAX

Aztreonam inhalation solution for suppressive treatment of chronicPseudomonas aeruginosalung infection in cystic fibrosis

(2011) Baroukh Maurice Assael   Expert Review of Anti-Infective Therapy

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

(2011) C.E. Wainwright et al.   Journal of Cystic Fibrosis

Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics

(2011) Manfred Ballmann et al.   RESPIRATORY MEDICINE

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronicPseudomonas aeruginosainfection in cystic fibrosis

(2011) Michael D Parkins et al.   Expert Review of Respiratory Medicine

Cystic fibrosis and survival to 40 years: a case-control study

(2010) N. J. Simmonds et al.   EUROPEAN RESPIRATORY JOURNAL

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

(2010) Michael W. Konstan et al.   Journal of Cystic Fibrosis

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial

(2010) Michael W. Konstan et al.   PEDIATRIC PULMONOLOGY

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

(2009) George Z. Retsch-Bogart et al.   CHEST

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

(2009) Harry Heijerman et al.   Journal of Cystic Fibrosis

Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements

(2009) Alexander Chuchalin et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Inhaled Aztreonam Lysine for Chronic AirwayPseudomonas aeruginosain Cystic Fibrosis

(2008) Karen S. McCoy et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

(2008) C.R. Hansen et al.   Journal of Cystic Fibrosis